Third Lawsuit Is Filed Against HRSA for Blocking the Rebate Model
11/19/2024 – Third Lawsuit Is Filed Against HRSA for Blocking the Rebate Model On November 14, 2024, Eli Lilly and Company (Lilly) filed a lawsuit against HHS and HRSA in…
J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model
11/14/2024 – J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model On November 12, 2024, Johnson and Johnson Health Care System Inc. (J&J) filed a lawsuit…
CMS Releases Physician Fee Schedule Final Rule for Calendar Year 2025 with Wins and Losses for Covered Entities
11/8/2024 – CMS Releases Physician Fee Schedule Final Rule for Calendar Year 2025 with Wins and Losses for Covered Entities On Friday November 1, 2024, CMS published the Calendar Year…
Boehringer Ingelheim Will Require Claims Data Submission for Single Contract Pharmacy
11/5/2024 – Beginning December 2, 2024, Boehringer Ingelheim Pharmaceuticals, Inc. (BI) will require covered entities to submit 340B claims data to 340B ESP™ for a single contract pharmacy. This policy applies…
VP of Pharmacy for Positive Impact Health Centers Emily Blaiklock on 340B Generic Drug Program for Rural/Ryan White Clinics WOYM 10-4
VP of Pharmacy for Positive Impact Health Centers Emily Blaiklock on 340B Generic Drug Program for Rural/Ryan White Clinics WOYM 10-4, listen to the interview here: https://wlds.com/audio/vp-of-pharmacy-for-positive-impact-health-centers-emily-blaiklock-on-340b-generic-drug-program-for-rural-ryan-white-clinics-woym-10-4/
CMS Guidance on Medicare Part D Maximum Fair Price
On October 2, 2024, CMS published final guidance on the implementation of the Medicare Part D price caps for the 2026 and 2027 calendar years under the Inflation Reduction Act…
Medicare Coverage of PrEP and Related Services
Effective September 30, 2024, CMS finalized its National Coverage Determination (NCD) for PrEP, which moves coverage for PrEP from Medicare Part D to Part B and requires reimbursement for certain…
J&J Pauses Rebate Model After HRSA Warning
Yesterday, Johnson & Johnson Health Care System Inc. (J&J) stated in a letter to HRSA that it will halt implementation of its proposed rebate model, which was set to take…
HRSA Denounces J&J’s Proposed Rebate Model
Today, the Health Resources and Services Administration (HRSA) issued a letter to Johnson and Johnson Health Care System Inc. (J&J) calling for the manufacturer to “cease implementation of its rebate…
AstraZeneca Will Require Submission of Claims Data to 340B ESP™ for Covered Entities to Designate Single Contract Pharmacy
Beginning October 1, 2024, AstraZeneca will require all covered entities to submit 340B claims utilization data to ESP™ as a pre-requisite for designating a single contract pharmacy. This announcement, released…